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Cardiovascular disease is the leading cause of death worldwide. One of the major risk factors for 
cardiovascular disease is hyperlipidemia. This study aimed to determine the potential of  
Zingiberaceae (10 species) as inhibitor of HMG-CoA reductase enzyme activity and lipid 
peroxidation. This study was conducted by 2 methods including assay of HMG-CoA reductase 
inhibition and lipid peroxidation test. The study was performed by in vitro method, using 20% rat liver 
homogenate. The inhibition of HMG-CoA  reductase enzyme was done by reacting liver homogenate, 
HMG-CoA  substrate, which added the Zingiberaceae extract compared with simvastatin as standard 
drug. The absorbance of the mixture was measured by a Microlab 300 spectrophotometer at a 340 nm 
wavelength. Lipid peroxidation assay was induced by the FeSO4.7H2O solution. The absorbance value 
measured using a spectrophotometer at a 532 nm wavelength. Lipid peroxidation inhibition was 
characterized by absorbance of the test extract, compared with the control group. The obtained data 
was calculated as percent of inhibition and was used to calculate IC50 extract test. The results showed 
that the 10 ethanolic extracts of Zingiberaceae rhizomes have activity as inhibitor HMG-CoA 
reductase enzyme with IC50 value range 65.8±4.1 – 203.3±15.2 ppm and IC50 for simvastatin as 
standard drug was 6.8±0.1 ppm. Inhibition of lipid peroxidation with IC50 value range 13.5±5.0 – 
219.6±4.3 ppm and simvastatin as standard drug was 1.8±0.5 ppm. This study can be concluded that 
the Zingiberaceae rhizomes have potential role as antihyperlipidemic agents through inhibition of 
HMG-CoA  reductase enzyme activity and preventing lipid peroxidation.  
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Cardiovascular disease is the leading cause of death worldwide. The World Health Organization 
(WHO) reports that hyperlipidemia is a major risk factor for cardiovascular disease and 
atherosclerosis. About 31% of deaths caused by cardiovascular disease include coronary heart disease 
and stroke (Mendis, Puska, Norrving, & Organization, 2011). The initial stage of coronary heart 
disease (CHD) is hyperlipidemia. Hyperlipidemia is a metabolic disorder indicated by an increase in 
total cholesterol, low-density lipoprotein (LDL), or triglycerides, and a decrease in high-density 
lipoprotein (HDL), or  combination of both in the blood (Wells, DiPiro, Schwinghammer, & DiPiro, 
2014). It has been found that there is an inverse relationship between HDL cholesterol levels and 
coronary heart disease risk (Rader & Hovingh, 2014). Moreover, the oxidized LDL lipoprotein 
(oxLDL) or lipid peroxidation in hyperlipidemia plays an important role in atherogenesis by increasing 
the lipid deposit in the arterial wall (Moriel et al., 2000). The presence of oxLDL is a biomarker of 
cardiovascular disease (Trpkovic et al., 2015). 
There is a relationship between the prevalence of hyperlipidemia and hypertension. 
Hypertension and hypertriglyceridemia are important components of the metabolic syndrome. 
Therefore, the increasing prevalence of these components leads to metabolic disease. Moreover, the 
relationship between blood pressure, central obesity, and the high levels of insulin, not only observed 
in adults, but has also been detected in children and adolescents. The increased prevalence of 
hyperlipidemia will be associated with the increasing prevalence of hypertension, result in the increase 
cardiovascular risk factors. Thus, cardiovascular disease can be prevented by preventing the main risk 
factor. (Bhalavi, Deshmukh, Atram, & Mahajan, 2014). 
HMG-CoA reductase is an enzyme that plays a role in controlling the biosynthesis of 
endogenous cholesterol in the liver. HMG-CoA reductase catalyzes HMG-CoA conversion into 
mevalonate, as a sterol precursor including cholesterol. The pathogenesis of hyperlipidemia may be 
due to hyperactivity of the HMG-CoA  reductase enzyme. This enzyme is a target of statin drugs, 
namely the class of HMG-CoA  reductase inhibitors. Statins work through inhibition of endogenous 
cholesterol biosynthesis in the liver thus increasing LDL receptor activity in the liver thereby 
increasing the clearance of LDL cholesterol in plasma. In addition, statins can also decrease LDL 
production by decreasing the production of very low-density lipoprotein (VLDL) in the liver. Statins 
as first-line hyperlipidemic drugs not only improve lipid profile but also improve vascular 
inflammation as the initial process of atherosclerosis (Blum, 2014). Therefore, drug research that can 
inhibit the enzyme HMG-CoA  reductase is very potential to be developed, especially from herbal 
medicines. 
The prevalence of hyperlipidemia is still high and increasing every year, especially in Indonesia, 
indicating that the existing treatment has not been able to control the disease. It is an opportunity to 
find a safer and more effective drug in treating hyperlipidemia, using Indonesian herbal medicine. 
Family Zingiberaceae has been used in Indonesia to overcome various diseases including 
hyperlipidemia. 
The Zingiberaceae family has held an important place for hundreds of years. Because of 
infusions and tinctures from these plants and other aromatic species have been used and are still used 
today as a component of herbal medicine to treat a variety of diseases (Tripathi & Singh, 2015). 
Zingiberaceae is a widely studied plant family and a potential source of medicinal plants. Various 
studies have shown that Zingiber officinale var rubrum has the potential to lower cholesterol, lower 
blood glucose levels and antioxidants (Srinivasan, 2017). Previous research has shown that 
Zingiberaceae can inhibit the alpha-glucosidase enzyme (Hasimun et al., 2016). This study aimed to 
determine the potential role of Zingiberaceae family (10 species) on the activity of HMG-CoA 
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MATERIALS AND METHODS 
Plant materials 
The study conducted using 10 species of Zingiberaceae namely: Zingiber littorale Nor., 
Zingiber aromaticum Val., Zingiber zerumbet (L) J.E.Smith., Zingiber cassumunar Roxb., Zingiber 
ottensi Val, Zingiber officinale Var officinarum, Zingiber officinale Var. Amarum., Zingiber officinale 
Var. Rubrum., Kaempferia galanga L., Alpinia galanga (L) Sw.This research uses rhizome plant parts. 
Zingiberaceae rhizome obtained from Manoko Lembang, Bandung, West Java. Plants have been 
carried out botanical identification in the Biology Laboratory, Faculty of Mathematics and Natural 
Sciences, Padjadjaran University, Bandung, West Java, Indonesia. 
 
Preparation extract 
The dried Zingiberaceae rhizomes were extracted using 96% ethanol solvent (purchased from 
Brataco, Bandung, Indonesia) by maceration method for 3 days. The filtrate was filtered, and 
concentrated using rotary evaporator at 60 °C and dried over a water bath at 60 ° C. 
 
Phytochemical screening 
Phytochemical screening was performed on ethanol extract of 10 Zingiberaceae rhizomes. 
Phytochemical screening aimed to identify classes of secondary metabolite compounds contained in 
Zingiberaceae rhizomes such as alkaloids, flavonoids, tannins, saponins, steroids. 
 
Experimental design 
Three Wistar 2-month-old male rats weighing 200-250 grams obtained from D'Wistar 
(Majalaya, Bandung, West Java, Indonesia). Test animals were acclimatized for 7 days in a cage with 
standard feed and drinking water, as well as 12 light dark duty cycles maintained. All treatments 
performed on test animals during the study were approved by the Ethical Committee of the Faculty of 
Medicine, Padjadjaran University, Bandung, West Java, Indonesia (No: 26/ UN6.C.10/PN/ 2018). 
After acclimatization, the rats were sacrificed and the liver organ were isolated to make 20% 
liver homogenate in buffer phosphate pH 7.4. 
 
HMG-CoA  reductase enzyme activity assays 
Prior to the test, a preliminary test of optimization of HMG-CoA substrate concentration was 
required to react with HMG-CoA  reductase enzyme in liver homogenate 20%. The preliminary test  
was conducted to determine the optimum substrate concentration to react with HMG-CoA  reductase 
enzyme. The results of the optimization obtained the substrate concentration required to activate 
HMG-CoA  reductase enzyme in a homogenate of 20% was 0.1 ppm. Then the optimum concentration 
of HMG-CoA  substrate was used to test enzyme activity in 20% homogenate of rat liver incubated 
with Zingiberaceae extract. 
The test was performed by making the homogenate of the liver isolated from the liver of the test 
animal. The isolated liver was cleansed by 0.9% NaCl. The cleansed and weighed liver was then cut 
into small pieces, and weighed to make 20% homogenate in phosphate buffer pH 7.4 and centrifuged 
at 8000 rpm, to form supernatant and residue. The supernatant was separated from the residue as a 
sample (homogenate).  
A 50 μL homogenate of 20% liver was added with 260 μL phosphate buffer pH 7.4, 42 μL 
Na2EDTA (purchased from Bratachem) 50 mM, 60 μL Dithiothreitol ((purchased from Sigma) 100 
mM, 50 μL KCl 2,16 M, 12 μL substrate HMG-CoA (purchased from Sigma). The mixture was vortex 
for 10 secs and incubated for 30 minutes (at 37°C). then added 55 NADPH (purchased from Sigma) 
1,105 mM and vortex for 10 secs and then incubation for 30 min (at 37
o
C) (Table I). The incubation 
process is carried out to ensure the reaction between the substrate and the enzyme HMG-CoA  
reductase as well as the test extract. The reaction will produce color with different intensity, the 
absorbance of the mixture was measured by a Microlab 300 spectrophotometer at a 340 nm 
wavelength. The presence of inhibition of HMG-CoA  reductase enzyme activity was characterized by 
decreasing sample absorbance value. 
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Lipid peroxidation assays 
The lipid peroxidation activity test follows Selvam et al. (1987) with slight modifications. Lipid 
peroxidation was induced by the FeSO4.7H2O solution. The short test procedure was as follows: 2.2 
mL of phosphate buffer pH 7.4, 0.2 mL FeSO4.7H2O 10 mM and 0.6 mL of liver homogenate were 
incubated in a mechanical shaker incubator at 37 ° C for 60 min. Added 0.5 mL of 40% trichloroacetic 
acid, 0.25 mL HCl 5 N and 0.5 mL 2% thiobarbituric acid. The mixture was stirred and then incubated 
in a water bath at 100 ° C for 10 minutes. The tube was cooled, then added 3 ml of chloroform and 
stirred. All test tubes were centrifuged at 2500 rpm for 10 minutes. The organic layer was separated 
(bottom). The supernatant absorbance was measured by spectrophotometer at 532 nm wavelength 
(Selvam & Kurien, 1987). 
 
Data Analysis 
The data obtained were shown as percent of inhibition. Increased percentage inhibition is 
proportional to the potential of the test extract as an inhibitor. Data was shown as the average value 
and standard deviation (n = 3). The IC50 was obtained by calculation of the percent value of inhibition 
at 3 different concentrations. 
 
RESULT AND DISCUSSION 
The extract yield of 10 Zingiberaceae rhizomes was obtained by maceration using 96% ethanol 
solvent for 3 days presented in Table I. The results of phytochemical screening of dried rhizomes are 
shown in Table II.  
 
Table I. The yield of rhizome extracts of 10 species from the Zingiberaceae family 
(macerated by 96% ethanol) 
 
Zingiberaceae Yield (%) 
Alpinia galanga (L) Sw. 1.6 
Kaempferia galanga L. 1.7 
Zingiber littorale Nor. 1.8 
Zingiber zerumbet (L) J.E.Smith. 1.9 
Zingiber officinale Var. Amarum 2.5 
Zingiber officinale Var. Officinarum 0.8 
Zingiber officinale Var. Rubrum 2.2 
Zingiber aromaticum Val. 1.2 
Zingiber ottensi Val. 2.8 
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Alkaloid Flavonoid Saponin Steroid Tanin 
Alpinia galanga (L) Sw. − − − − + 
Kaempferia galanga L. − − − + + 
Zingiber aromaticum Val. − + + − + 
Zingiber cassmunar Roxb. − + − − + 
Zingiber littorale Nor. + − + − + 
Zingiber officinale Var. Amarum − + − + − 
Zingiber officinale Var. 
Officinarum 
+ + − − + 
Zingiber officinale Var. Rubrum. + + − − + 
Zingiber ottensi Val − + − + + 
Zingiber zerumbet (L) J.E.Smith. − + + + − 
 (+): present , (-): absent 
 
Zingiberaceae rhizomes as inhibitor HMG-CoA  Reductase  
The addition of Zingiberaceae extract to rat liver homogenate decreases the activity of HMG-
CoA reductase enzyme  indicated  by decreased absorbance value of  NADPH. This occurs because of 
inhibition of HMG-CoA reductase enzyme activity by Zingiberaceae extract where this enzyme 
activity always requires NADPH as a cofactor. NADPH undergoes an oxidation-reduction reaction 
that will be converted to NADP
+
 and produces a color reaction when the active HMG-CoA reductase 
enzyme converts HMG-CoA into mevalonic acid and then converted to cholesterol.  
The percent of inhibition obtained from the absorbance value was used to calculate the IC50 
value of the Zingiberaceae extract. IC50 value shows the amount of Zingiberaceae extract concentration 
that can inhibit the activity of HMG-CoA Reductase enzyme by 50 percent. The smaller 
concentrations of IC50 indicate that the stronger activity of  extract as an HMG-CoA reductase enzyme 
inhibitor (Table III). 
 
Table III. IC50 concentration of Zingiberaceae rhizome as HMG-CoA reductase inhibitor 
 
Zingiberaceae IC50 (ppm) 
Simvastatin     6.8 ±  0.1 
Zingiber officinale Var. Rubrum   65.8 ±  4.1 
Zingiber littorale Nor.   73.0 ±   8.7 
Zingiber cassumunar Roxb.   73.6 ±  8.7 
Zingiber ottensi Val.   74.1 ±  6.0 
Zingiber officinale Var. Officinarum   74.2 ± 13.6 
Zingiber officinale Var. Amarum   76.7 ±  2.8 
Zingiber aromaticum Val.   88.1 ±  2.2 
Zingiber zerumbet (L) J.E.Smith.   89.1±   5.3 
Alpinia galanga (L) Sw. 199.6 ±  6.5 
Kaempferia galanga L. 203.3 ± 15.2 
Values are expressed as mean and error bar (n=3). 
IC50 obtained from regression line of percentage inhibition. 
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Previous studies have reported that extract of Zingiber officinale Rosc. decreased liver enzyme 
activity such as AST, ALT, ALP and LDH, which increases due to iron accumulation in the liver 
(Gholampour, Ghiasabadi, Owji, & Vatanparast, 2017). Other studies have reported that the ethanol 
extract leaves Zingiber officinale Rosc has potent antioxidant activity (Tohma et al., 2017). Clinical 
studies in patients with type 2 diabetes mellitus, supplementation of Zingiber officinale improves 
glycemic control of patients. Its therapeutic effects occur through various mechanisms including 
inhibiting lipid peroxidation (Shidfar et al., 2015). Therefore, supplementation of Zingiber officinale 
may reduce the risk of chronic complications of diabetes (Khandouzi et al., 2015). 
This study showed that the most potent inhibition potential of Zingiberaceae extracts against 
HMG-CoA reductase and lipid peroxidation activity are Zingiber officinale Var. Rubrum. and Zingiber 
littorale Nor. The effect of red ginger (Zingiber officinale Var. Rubrum) as an inhibitor of HMG-CoA  
reductase supports the results of previous studies which reported that red ginger has 
antihyperlipidemic activity capable of reducing total cholesterol and triglyceride levels and increasing 
HDL levels (Safitri, Kurniati, Adharani, Suciyati, & Adnyana, 2016). Zingiber littorale is one of 3 
types of Zingiber zerumbet variants. The activity of Zingiber littorale as an inhibitor of HMG-CoA  
reductase enzyme, was first reported in this study. The results of previous studies showed that 
zerumbone, a sesquiterpene of Zingiber zerumbet Smith, was reported as an active compound that 
plays an important role in the inhibitory effect of the HMG-CoA  reductase enzyme (Tzeng, Lu, Liou, 
Chang, & Liu, 2014) 
 
CONCLUSION  
Based on the results of this study can be concluded that Zingiberaceae rhizome ethanol extract 
has antihyperlipidemic activity through the mechanism of inhibition of liver enzyme HMG-CoA  
reductase and prevent lipid peroxidation therefore it may have potential activitiy as anti-
hyperlipidemia and anti-atherosclerosis.  
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